SG Americas Securities LLC Increases Stock Holdings in AxoGen, Inc. $AXGN

Key Points

• SG Americas Securities LLC increased its stake in AxoGen by 459.9% in Q4 to 65,480 shares (about $2.14M), as institutional ownership now stands at 80.29% after large purchases by firms like First Light and Balyasny.
• Wall Street sentiment is largely positive—nine Buy ratings vs. one Sell—giving a consensus rating of Moderate Buy and a consensus price target of $39.75, with recent upgrades and new coverage from several brokers.
• AxoGen trades near $34.44 (12‑month range $9.22–$36) with a $1.79B market cap; the company reported a slight quarterly EPS miss, remains loss-making (negative margins), and is forecast to post about -0.29 EPS for the fiscal year.

SG Americas Securities LLC boosted its position in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 459.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 65,480 shares of the medical equipment provider's stock after purchasing an additional 53,786 shares during the quarter. SG Americas Securities LLC owned about 0.14% of AxoGen worth $2,143,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. First Light Asset Management LLC raised its position in shares of AxoGen by 28.2% during the 3rd quarter. First Light Asset Management LLC now owns 5,805,730 shares of the medical equipment provider's stock valued at $103,574,000 after buying an additional 1,276,487 shares during the period. Balyasny Asset Management L.P. lifted its position in shares of AxoGen by 183.9% during the second quarter. Balyasny Asset Management L.P. now owns 1,931,158 shares of the medical equipment provider's stock worth $20,953,000 after purchasing an additional 1,250,968 shares in the last quarter. Bessemer Group Inc. acquired a new stake in AxoGen during the 3rd quarter worth approximately $14,468,000. Wasatch Advisors LP boosted its holdings in AxoGen by 85.1% in the second quarter. Wasatch Advisors LP now owns 1,433,782 shares of the medical equipment provider's stock valued at $15,557,000 after purchasing an additional 659,149 shares during the period. Finally, Brown Capital Management LLC acquired a new position in shares of AxoGen during the third quarter worth about $11,500,000. Hedge funds and other institutional investors own 80.29% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on AXGN. Citizens Jmp increased their price objective on shares of AxoGen from $34.00 to $42.00 and gave the company a "market outperform" rating in a research report on Tuesday, February 24th. Wells Fargo & Company began coverage on AxoGen in a report on Thursday, February 19th. They issued an "overweight" rating and a $40.00 price objective for the company. Canaccord Genuity Group reissued a "buy" rating and set a $40.00 price target on shares of AxoGen in a report on Monday, March 30th. Citigroup reiterated an "outperform" rating on shares of AxoGen in a research note on Tuesday, February 24th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of AxoGen in a research report on Monday, December 29th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $39.75.

AxoGen Price Performance

Shares of AxoGen stock opened at $34.44 on Friday. AxoGen, Inc. has a twelve month low of $9.22 and a twelve month high of $36.00. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -101.29 and a beta of 0.98. The company has a current ratio of 5.11, a quick ratio of 3.31 and a debt-to-equity ratio of 0.51. The company has a fifty day moving average price of $32.80 and a 200 day moving average price of $27.90.

AxoGen (NASDAQ:AXGN - Get Free Report) last posted its earnings results on Tuesday, February 24th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.08 by ($0.01). AxoGen had a negative net margin of 6.97% and a negative return on equity of 13.44%. The company had revenue of $59.90 million during the quarter, compared to analyst estimates of $59.90 million. Equities research analysts forecast that AxoGen, Inc. will post -0.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Erick Wayne Devinney sold 5,221 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $32.84, for a total value of $171,457.64. Following the completion of the sale, the insider directly owned 262,781 shares of the company's stock, valued at $8,629,728.04. The trade was a 1.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.78% of the stock is currently owned by corporate insiders.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen's offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company's core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.

Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.